Form 4: Envoy Medical Director Granted New Stock Options

Envoy Medical Director Janis Smith-Gomez was granted 25,000 Class A Common Stock options with an exercise price of $0.813, expiring in 2035.

Summary

• Janis Smith-Gomez, a Director at Envoy Medical, Inc. (COCH), reported changes in beneficial ownership of derivative securities.
• On December 3, 2025, Smith-Gomez was granted 25,000 stock options to purchase Class A Common Stock.
• These newly granted options have an exercise price of $0.813 per share and are set to expire on December 3, 2035.
• The new options become exercisable on May 1, 2026.
• Smith-Gomez also beneficially owns another 25,000 stock options with an exercise price of $2.40, which expire on October 15, 2033.
• The older options have a vesting schedule where 6,250 shares vest on October 15, 2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

Sentiment

Score: 7

Explanation: The grant of new stock options to a director is generally a positive signal, indicating continued commitment and alignment of interests. The lower exercise price of the new options could be seen favorably.

Positives

• A director receiving new stock options can signal continued commitment and alignment with shareholder interests.
• The new options have a lower exercise price ($0.813) compared to previously held options ($2.40), potentially indicating a favorable grant price or a reflection of current stock valuation.

Risks

• The value of stock options is dependent on the future performance of Envoy Medical's Class A Common Stock.
• If the stock price does not rise above the exercise price, the options may expire worthless.

Future Outlook

The granting of new stock options to a director suggests a long-term incentive structure aimed at aligning management's interests with future company growth and shareholder value creation.

Industry Context

Stock option grants are a common form of executive and director compensation in publicly traded companies, particularly in growth-oriented sectors like medical technology, to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in many industries, including medical technology, to align their interests with long-term shareholder value.
• The specific terms (exercise price, vesting schedule, expiration) would typically be benchmarked against peer companies in the medical device or biotech sector, such as Cochlear Limited, GN Store Nord, or Sonova Holding AG, to ensure competitive and motivating compensation.
• The exercise price of $0.813 for the new options, compared to the older options at $2.40, suggests a potential adjustment based on the company's stock performance or a new valuation at the time of the grant.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential for increased director alignment with shareholder value creation.
• Employees: No direct impact mentioned for general employees.

Next Steps

• Monitor the vesting schedule of the granted options.
• Observe future stock price performance relative to the option exercise prices.

Key Dates

Keywords

Envoy Medical, COCH, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership